Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01261169|
Recruitment Status : Unknown
Verified December 2010 by Genovate Biotechnology Co., Ltd.,.
Recruitment status was: Recruiting
First Posted : December 16, 2010
Last Update Posted : December 16, 2010
|Condition or disease||Intervention/treatment|
This study is a single arm prospective evaluation in which patients with uveitis are treated with Myfortic® in a dose of 360 mg bid for six months. From day 0, Myfortic will be combined with 1 mg/kg prednisone. Prednisone will be tapered from week 1 based on the clinical findings of the ophthalmologist.
There will be no other stratification of patients. After the screening, patients will be treated with Myfortic® for 6 months. Patients will be seen at month 1, 3, and 6. Thereafter patients will be followed up at month 12. Efficacy and safety assessments will be performed at each visit.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study|
|Study Start Date :||January 2009|
|Estimated Study Completion Date :||December 2011|
Myfortic in uveitis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01261169
|Contact: Hwang Yih Shiou, MD||886-3-3281200 ext firstname.lastname@example.org|
|Taoyuan County, Taiwan, 333|
|Contact: Hwang Yih Shiou, MD 886-3-3281200 ext 8666 email@example.com|
|Principal Investigator:||Hwang Yih Shiou, MD||CGMH|